B-type natriuretic peptide levels and benign adiposity in obese heart failure patients

Area of Science:

• Cardiology
• Metabolic Syndrome
• Obesity Research

Background:

• Obesity is a significant risk factor for chronic heart failure (CHF).
• Obese patients with CHF paradoxically exhibit a better prognosis than their non-obese counterparts.
• Adipose tissue in heart failure (HF) patients is not uniformly detrimental, with some exhibiting benign adiposity.

Purpose of the Study:

• To review the literature on the bidirectional relationship between brain natriuretic peptide (BNP) and adipose tissue in heart failure (HF).
• To explore how natriuretic peptides (NPs) mediate communication between the heart and adipose tissue.
• To highlight the complex interplay and implications for HF management.

Main Methods:

• Literature review of experimental and clinical studies.
• Analysis of data on natriuretic peptides (NPs) and adipose tissue function.
• Examination of body fat distribution and its impact on the NP-adipose tissue axis.

Main Results:

• Natriuretic peptides (NPs), especially BNP, are key mediators between cardiac and adipose tissues.
• Adipose tissue exhibits heterogeneity in function and distribution, influencing the NP-adipose axis.
• NPs can promote a healthy adipocyte phenotype and favorably modulate body fat metabolism.

Conclusions:

• The relationship between obesity, heart failure, and natriuretic peptides is complex and multifactorial.
• BNP plays a crucial role in modulating adipose tissue, potentially contributing to the "obesity paradox" in heart failure.
• Understanding this bidirectional communication is vital for developing novel therapeutic strategies for heart failure.